Core Viewpoint - Sino Medical achieved a significant stock price increase of 19.99% on August 18, reaching a price of 41.48 CNY per share, with a trading volume of 2.032 billion CNY and a turnover rate of 12.37%, resulting in a total market capitalization of 17.258 billion CNY [1] Company Overview - Sino Medical Technology Co., Ltd. is located in the Tianjin Economic-Technological Development Area and specializes in the research, production, and sales of high-end interventional medical devices [1] - The company’s main products include coronary drug-eluting stents, coronary balloons, intracranial rapid exchange balloons, and intracranial drug-eluting stents, with over 1.4 million units used globally, serving hundreds of thousands of patients [1] - Sino Medical holds 8 key technologies, has launched 19 products, and possesses over 200 global patents, while undertaking 7 national and provincial scientific research projects [1] - Clinical research results of its products have been published in 31 articles in core domestic and international journals [1] Financial Performance - For the period from January to March 2025, Sino Medical reported a revenue of 101 million CNY, representing a year-on-year growth of 10.75% [1] - The net profit attributable to shareholders was 2.9693 million CNY, showing a substantial year-on-year increase of 277.50% [1] - As of March 31, the number of shareholders was 11,000, with an average of 37,400 circulating shares per person [1]

Core Viewpoint - Sino Medical achieved a significant stock price increase of 19.99%, reaching 30.13 CNY per share, with a trading volume of 3.005 billion CNY and a turnover rate of 26.34%, resulting in a total market capitalization of 12.536 billion CNY [1] Company Overview - Sino Medical Science and Technology Co., Ltd. is located in Tianjin Development Zone and specializes in the research, production, and sales of high-end interventional medical devices [1] - The company’s main products include coronary drug-eluting stents, coronary balloons, intracranial rapid exchange balloons, and intracranial drug-eluting stents, with over 1.4 million units used globally, serving hundreds of thousands of patients [1] - Sino Medical holds 8 key technologies, has launched 19 products, and possesses over 200 global patents, while undertaking 7 national and provincial scientific research projects [1] - Clinical research results have been published in 31 articles in core domestic and international journals [1] Financial Performance - For the first quarter of 2025, Sino Medical reported a revenue of 101 million CNY, representing a year-on-year growth of 10.75% [1] - The net profit attributable to shareholders was 2.9693 million CNY, showing a substantial year-on-year increase of 277.50% [1] - As of March 31, the number of shareholders was 11,000, with an average of 37,400 circulating shares per person [1]

Core Points - The company, Sino Medical Science and Technology Co., Ltd., is preparing for its 2024 Annual General Meeting (AGM) to ensure the rights of all shareholders and maintain order during the meeting [1][2][3] - The company reported a significant increase in revenue and net profit for 2024, with total assets reaching 1.3 billion yuan and net assets of 898 million yuan [8][9][10] - The company achieved a revenue of 459 million yuan, a year-on-year increase of 33.64%, and a net profit attributable to shareholders of 1.4978 million yuan, up 103.78% [8][10][12] - The company has established a strong international presence, with its products registered in 26 countries and regions, and overseas sales revenue growing by 72.38% [13][14] Meeting Procedures - The AGM will be held on May 19, 2025, with both on-site and online voting options available for shareholders [5][6] - Shareholders must arrive 30 minutes before the meeting to complete registration and present necessary documentation [2][3] - The meeting will follow a structured agenda, including the announcement of attendees, discussion of proposals, and voting [7][8] Financial Performance - The company reported total assets of 1.3 billion yuan and total liabilities of 402 million yuan, reflecting a 9.68% and 24.08% increase year-on-year, respectively [9][10] - The company’s main products, including coronary drug-eluting stents and intracranial stents, have seen significant sales growth, with coronary business revenue increasing by 59.19% [12][14] - The company has focused on innovation, with 22 new patents granted during the reporting period, enhancing its competitive edge in the medical device market [14][15] Governance and Compliance - The board of directors has held six meetings in 2024, ensuring compliance with relevant laws and regulations [24][30] - The company emphasizes the importance of independent directors, with three independent directors actively participating in board meetings [24][30] - The company has implemented robust internal controls to manage risks and ensure compliance with financial regulations [31]